{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T19:32:10Z","timestamp":1792438330239,"version":"4.5.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The Aurora-A kinase and its major regulator TPX2 act as key players during mitosis. Both are overexpressed in tumors, and the Aurora-A\/TPX2 complex has been proposed as a potential oncogenic holoenzyme. Evidence of Aurora-A non-mitotic roles in cancer, some of which depend on its nuclear accumulation in interphase and are independent from the kinase activity, is emerging. Indeed, many Aurora-A ATP-competitive inhibitors have shown limited efficacy in clinical trials so far, highlighting the need for novel strategies to inhibit Aurora-A. Interestingly, our recent results suggest an involvement of TPX2 also in the non-mitotic protumorigenic roles of Aurora-A, which makes the Aurora-A\/TPX2 complex a promising target. We previously described Aurora-A\/TPX2 protein-protein interaction inhibitors. Here, starting from in silico analyses, we identified a new compound, i.e., ATC12, which we validated in vitro as a molecule able to bind Aurora-A and to compete with TPX2. We investigated the effects of ATC12 in 2D cultures and 3D mammospheres of breast cancer cell lines, as well as in patient-derived organoids, and observed an impairment of Aurora-A\/TPX2 interaction and a decrease in cell viability and proliferation. Altogether, our observations support the targeting of the Aurora-A\/TPX2 complex as a promising strategy for the development of novel anti-cancer therapeutics.<\/jats:p>","DOI":"10.1038\/s41419-026-08579-3","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T14:50:50Z","timestamp":1774363850000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The ATC12 small molecule inhibits the Aurora-A\/TPX2 interaction and impairs the proliferation of breast cancer cells"],"prefix":"10.1038","volume":"17","author":[{"given":"Dalila","family":"Boi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Fianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Polverino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3550-1860","authenticated-orcid":false,"given":"Francesco","family":"Fiorentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Mastrangelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2869-5627","authenticated-orcid":false,"given":"Simone","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Rubini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0164-8998","authenticated-orcid":false,"given":"Serena","family":"Rosignoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Troilo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosaria","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalila","family":"Tarquini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cervoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0682-023X","authenticated-orcid":false,"given":"Serena","family":"Rinaldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5625-1170","authenticated-orcid":false,"given":"Angela","family":"Tramonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora Kristina","family":"Scarpone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Naro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2864-8266","authenticated-orcid":false,"given":"Claudio","family":"Sette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3971-0398","authenticated-orcid":false,"given":"Venturina","family":"Stagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9913-0635","authenticated-orcid":false,"given":"Gianni","family":"Colotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dante","family":"Rotili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9078-7545","authenticated-orcid":false,"given":"Alessandro","family":"Paiardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7541-8183","authenticated-orcid":false,"given":"Giulia","family":"Guarguaglini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6582-5500","authenticated-orcid":false,"given":"Italia Anna","family":"Asteriti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"8579_CR1","doi-asserted-by":"publisher","first-page":"120185","DOI":"10.1098\/rsob.120185","volume":"3","author":"H Hochegger","year":"2013","unstructured":"Hochegger H, H\u00e9garat N, Pereira-Leal JB. Aurora at the pole and equator: overlapping functions of Aurora kinases in the mitotic spindle. Open Biol. 2013;3:120185.","journal-title":"Open Biol"},{"key":"8579_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13008-018-0040-6","volume":"13","author":"E Willems","year":"2018","unstructured":"Willems E, Dedobbeleer M, Digregorio M, Lombard A, Lumapat PN, Rogister B. The functional diversity of Aurora kinases: a comprehensive review. Cell Div. 2018;13:7.","journal-title":"Cell Div"},{"key":"8579_CR3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/biom9010028","volume":"9","author":"L Magnaghi-Jaulin","year":"2019","unstructured":"Magnaghi-Jaulin L, Eot-Houllier G, Gallaud E, Giet R. Aurora a protein kinase: to the centrosome and beyond. Biomolecules. 2019;9:28.","journal-title":"Biomolecules"},{"key":"8579_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00651-4","volume":"12","author":"K Nikhil","year":"2024","unstructured":"Nikhil K, Shah K. The significant others of Aurora kinase in cancer: combination is the key. Biomark Res. 2024;12:109.","journal-title":"Biomark Res"},{"key":"8579_CR5","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1083\/jcb.200204155","volume":"158","author":"TA Kufer","year":"2002","unstructured":"Kufer TA, Sillj\u00e9 HHW, K\u00f6rner R, Gruss JO, Meraldi P, Nigg EN. Human TPX2 is required for targeting Aurora-A kinase to the spindle. J Cell Biol. 2002;158:617\u201323.","journal-title":"J Cell Biol"},{"key":"8579_CR6","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S1097-2765(03)00392-7","volume":"12","author":"R Bayliss","year":"2003","unstructured":"Bayliss R, Sardon T, Vernos I, Conti E. Structural basis of Aurora-A activation by TPX2 at the mitotic spindle. Mol Cell. 2003;12:851\u201362.","journal-title":"Mol Cell"},{"key":"8579_CR7","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1083\/jcb.200312112","volume":"166","author":"OJ Gruss","year":"2004","unstructured":"Gruss OJ, Vernos I. The mechanism of spindle assembly: functions of Ran and its target TPX2. J Cell Biol. 2004;166:949\u201355.","journal-title":"J Cell Biol"},{"key":"8579_CR8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1242\/jcs.075457","volume":"124","author":"M Giubettini","year":"2011","unstructured":"Giubettini M, Asteriti IA, Scrofani J, De Luca M, Lindon C, Lavia P, et al. Control of Aurora-A stability through interaction with TPX2. J Cell Sci. 2011;124:113\u201322.","journal-title":"J Cell Sci"},{"key":"8579_CR9","doi-asserted-by":"crossref","unstructured":"Chen M, Zhu H, Li J, Luo D, Zhang J, Liu W, et al. Research progress on the relationship between AURKA and tumorigenesis: the neglected nuclear function of AURKA. Ann Med. 2024;56:2282184.","DOI":"10.1080\/07853890.2023.2282184"},{"key":"8579_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.130913","volume":"265","author":"D Gupta","year":"2024","unstructured":"Gupta D, Kumar M, Saifi S, Rawat S, Ethayathulla AS, Kaur P. A comprehensive review on role of Aurora kinase inhibitors (AKIs) in cancer therapeutics. Int J Biol Macromol. 2024;265:130913.","journal-title":"Int J Biol Macromol"},{"key":"8579_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01305-3","volume":"20","author":"R Du","year":"2021","unstructured":"Du R, Huang C, Liu K, Li X, Dong Z. Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy. Mol Cancer. 2021;20:15.","journal-title":"Mol Cancer"},{"key":"8579_CR12","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1016\/j.apsb.2023.03.013","volume":"13","author":"D Zheng","year":"2023","unstructured":"Zheng D, Li J, Yan H, Zhang G, Li W, Chu E, et al. Emerging roles of Aurora-A kinase in cancer therapy resistance. Acta Pharm Sin B. 2023;13:2826\u201343.","journal-title":"Acta Pharm Sin B"},{"key":"8579_CR13","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/s12276-021-00635-6","volume":"53","author":"PK Mou","year":"2021","unstructured":"Mou PK, Yang EJ, Shi C, Ren G, Tao S, Shim JS. Aurora kinase A, a synthetic lethal target for precision cancer medicine. Exp Mol Med. 2021;53:835\u201347.","journal-title":"Exp Mol Med"},{"key":"8579_CR14","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1200\/JCO.18.00899","volume":"37","author":"OA O\u2019Connor","year":"2019","unstructured":"O\u2019Connor OA, \u00d6zcan M, Jacobsen ED, Roncero JM, Trotman J, Demeter J, et al. Randomized phase III study of alisertib or investigator\u2019s choice (selected single agent) in patients with relapsed or refractory peripheral T-cell lymphoma. J Clin Oncol. 2019;37:613\u201323.","journal-title":"J Clin Oncol"},{"key":"8579_CR15","first-page":"202003000006","volume":"6","author":"A Lin","year":"2020","unstructured":"Lin A, Summers D, Reiff SB, Tipton AR, Tang SK, Marshall WF. Aurora kinase inhibitors delay regeneration in Stentor coeruleus at an intermediate step. Matters Sel. 2020;6:202003000006.","journal-title":"Matters Sel"},{"key":"8579_CR16","doi-asserted-by":"crossref","unstructured":"Falchook G, Coleman R L, Roszak A, Behbakht K, Matulonis U, Ray-Coquard I, et al. Alisertib in combination with weekly paclitaxel in patients with advanced breast cancer or recurrent ovarian cancer: a randomized clinical trial. JAMA Oncol. 2019;5:e183773.","DOI":"10.1001\/jamaoncol.2018.3773"},{"key":"8579_CR17","doi-asserted-by":"publisher","first-page":"6229","DOI":"10.18632\/oncotarget.2190","volume":"5","author":"IA Asteriti","year":"2014","unstructured":"Asteriti IA, Di Cesare E, De Mattia F, Hilsenstein V, Neumann B, Cundari E, et al. The Aurora-A inhibitor MLN8237 affects multiple mitotic processes and induces dose-dependent mitotic abnormalities and aneuploidy. Oncotarget. 2014;5:6229\u201342.","journal-title":"Oncotarget"},{"key":"8579_CR18","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.pbiomolbio.2015.01.009","volume":"119","author":"H Jubb","year":"2015","unstructured":"Jubb H, Blundell TL, Ascher DB. Flexibility and small pockets at protein-protein interfaces: new insights into druggability. Prog Biophys Mol Biol. 2015;119:2\u20139.","journal-title":"Prog Biophys Mol Biol"},{"key":"8579_CR19","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.2147\/CMAR.S402572","volume":"15","author":"J Wu","year":"2023","unstructured":"Wu J, Luo H, Wang K, Yi B. Development and validation of a novel diagnostic nomogram model using serum oxidative stress markers and AURKA for prediction of nasopharyngeal carcinoma. Cancer Manag Res. 2023;15:1053\u201362.","journal-title":"Cancer Manag Res"},{"key":"8579_CR20","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.bbcan.2010.08.001","volume":"1806","author":"IA Asteriti","year":"2010","unstructured":"Asteriti IA, Rensen WM, Lindon C, Lavia P, Guarguaglini G. The Aurora-A\/TPX2 complex: a novel oncogenic holoenzyme? Biochim Biophys Acta Rev Cancer. 2010;1806:230\u20139.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"8579_CR21","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1177\/1947601912473306","volume":"3","author":"IP De Castro","year":"2012","unstructured":"De Castro IP, Malumbres M. Mitotic stress and chromosomal instability in cancer: the case for TPX2. Genes Cancer. 2012;3:721\u201373.","journal-title":"Genes Cancer"},{"key":"8579_CR22","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.3390\/cells13161397","volume":"13","author":"F Polverino","year":"2024","unstructured":"Polverino F, Mastrangelo A, Guarguaglini G. Contribution of AurkA\/TPX2 overexpression to chromosomal imbalances and cancer. Cells. 2024;13:1397.","journal-title":"Cells"},{"key":"8579_CR23","doi-asserted-by":"crossref","unstructured":"Jane\u010dek M, Rossmann M, Sharma P, Emery A, Huggins DJ, Stockwell SR, et al. Allosteric modulation of AURKA kinase activity by a small-molecule inhibitor of its protein-protein interaction with TPX2. Sci Rep. 2016;6:28528.","DOI":"10.1038\/srep28528"},{"key":"8579_CR24","doi-asserted-by":"publisher","first-page":"32117","DOI":"10.18632\/oncotarget.16738","volume":"8","author":"IA Asteriti","year":"2017","unstructured":"Asteriti IA, Daidone F, Colotti G, Rinaldo S, Lavia P, Guarguaglini G, et al. Identification of small molecule inhibitors of the Aurora-A\/TPX2 complex. Oncotarget. 2017;8:32117\u201333.","journal-title":"Oncotarget"},{"key":"8579_CR25","doi-asserted-by":"publisher","first-page":"15521","DOI":"10.1021\/acs.jmedchem.4c01165","volume":"67","author":"SR Stockwell","year":"2024","unstructured":"Stockwell SR, Scott DE, Fischer G, Guarino E, Rooney TPC, Feng TS, et al. Selective Aurora A-TPX2 interaction inhibitors have in vivo efficacy as targeted antimitotic agents. J Med Chem. 2024;67:15521\u201336.","journal-title":"J Med Chem"},{"key":"8579_CR26","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s00018-019-03310-2","volume":"77","author":"G Bertolin","year":"2020","unstructured":"Bertolin G, Tramier M. Insights into the non-mitotic functions of Aurora kinase A: more than just cell division. Cell Mol Life Sci. 2020;77:1031\u201347.","journal-title":"Cell Mol Life Sci"},{"key":"8579_CR27","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.1038\/s41388-021-01766-w","volume":"40","author":"FD Naso","year":"2021","unstructured":"Naso FD, Boi D, Ascanelli C, Pamfil G, Lindon C, Paiardini A, et al. Nuclear localisation of Aurora-A: its regulation and significance for Aurora-A functions in cancer. Oncogene. 2021;40:3917\u201328.","journal-title":"Oncogene"},{"key":"8579_CR28","doi-asserted-by":"crossref","unstructured":"Asteriti IA, Polverino F, Stagni V, Sterbini V, Ascanelli C, Naso FD, et al. AurkA nuclear localization is promoted by TPX2 and counteracted by protein degradation. Life Sci Alliance. 2023;6:e202201726.","DOI":"10.26508\/lsa.202201726"},{"key":"8579_CR29","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1107\/S2053230X15002290","volume":"71","author":"SG Burgess","year":"2015","unstructured":"Burgess SG, Bayliss R. The structure of C290A: C393A Aurora A provides structural insights into kinase regulation. Acta Crystallogr F Struct Biol Commun. 2015;71:315\u20139.","journal-title":"Acta Crystallogr F Struct Biol Commun"},{"key":"8579_CR30","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/jcb.30205","volume":"123","author":"I Kahl","year":"2022","unstructured":"Kahl I, Mense J, Finke C, Boller AL, Lorber C, Gy\u0151rffy B, et al. The cell cycle-related genes RHAMM, AURKA, TPX2, PLK1, and PLK4 are associated with the poor prognosis of breast cancer patients. J Cell Biochem. 2022;123:581\u2013600.","journal-title":"J Cell Biochem"},{"key":"8579_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-13-63","volume":"13","author":"C Gest","year":"2013","unstructured":"Gest C, Joimel U, Huang L, Pritchard LL, Petit A, Dulong C, et al. Rac3 induces a molecular pathway triggering breast cancer cell aggressiveness: differences in MDA-MB-231 and MCF-7 breast cancer cell lines. BMC Cancer. 2013;13:1\u201314.","journal-title":"BMC Cancer"},{"key":"8579_CR32","first-page":"3147","volume":"35","author":"Com\u015fa \u015e","year":"2015","unstructured":"Com\u015fa \u015e, C\u00eempean AM, Raica M. The story of MCF-7 breast cancer cell line: 40 years of experience in research. Anticancer Res. 2015;35:3147\u201354.","journal-title":"Anticancer Res"},{"key":"8579_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-10-449","volume":"10","author":"J Mladkova","year":"2010","unstructured":"Mladkova J, Sanda M, Matouskova E, Selicharova I. Phenotyping breast cancer cell lines EM-G3, HCC1937, MCF7 and MDA-MB-231 using 2-D electrophoresis and affinity chromatography for glutathione-binding proteins. BMC Cancer. 2010;10:1\u201310.","journal-title":"BMC Cancer"},{"key":"8579_CR34","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1159\/000485344","volume":"44","author":"Y Shi","year":"2017","unstructured":"Shi Y, Ye P, Long X. Differential expression profiles of the transcriptome in breast cancer cell lines revealed by next generation sequencing. Cell Physiol Biochem. 2017;44:804\u201316.","journal-title":"Cell Physiol Biochem"},{"key":"8579_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10180","volume":"7","author":"F Zheng","year":"2016","unstructured":"Zheng F, Yue C, Li G, He B, Cheng W, Wang X, et al. Nuclear AURKA acquires a kinase-independent transactivating function to enhance breast cancer stem cell phenotype. Nat Commun. 2016;7:10180. 7.","journal-title":"Nat Commun"},{"key":"8579_CR36","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/cac2.12509","volume":"44","author":"B Cesaro","year":"2024","unstructured":"Cesaro B, Iaiza A, Piscopo F, Tarullo M, Cesari E, Rotili D, et al. Enhancing sensitivity of triple-negative breast cancer to DNA-damaging therapy through chemical inhibition of the m6A methyltransferase METTL3. Cancer Commun. 2024;44:282\u20136.","journal-title":"Cancer Commun"},{"key":"8579_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114751","volume":"43","author":"C Caggiano","year":"2024","unstructured":"Caggiano C, Petrera V, Ferri M, Pieraccioli M, Cesari E, Di Leone A, et al. Transient splicing inhibition causes persistent DNA damage and chemotherapy vulnerability in triple-negative breast cancer. Cell Rep. 2024;43:114751.","journal-title":"Cell Rep"},{"key":"8579_CR38","doi-asserted-by":"publisher","first-page":"3428","DOI":"10.1038\/onc.2016.490","volume":"36","author":"N Yang","year":"2017","unstructured":"Yang N, Wang C, Wang Z, Zona S, Lin SX, Wang X, et al. FOXM1 recruits nuclear Aurora kinase A to participate in a positive feedback loop essential for the self-renewal of breast cancer stem cells. Oncogene. 2017;36:3428\u201340.","journal-title":"Oncogene"},{"key":"8579_CR39","first-page":"1","volume":"9","author":"H Nada","year":"2024","unstructured":"Nada H, Choi Y, Kim S, Jeong KS, Meanwell NA, Lee K, et al. New insights into protein\u2013protein interaction modulators in drug discovery and therapeutic advance. Signal Transduct Target Ther. 2024;9:1\u201332.","journal-title":"Signal Transduct Target Ther"},{"key":"8579_CR40","doi-asserted-by":"publisher","first-page":"5651","DOI":"10.1038\/s41388-021-01969-1","volume":"40","author":"KM Whately","year":"2021","unstructured":"Whately KM, Voronkova MA, Maskey A, Gandhi J, Loskutov J, Choi H, et al. Nuclear Aurora-A kinase-induced hypoxia signaling drives early dissemination and metastasis in breast cancer: implications for detection of metastatic tumors. Oncogene. 2021;40:5651\u201364.","journal-title":"Oncogene"},{"key":"8579_CR41","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/onc.2017.304","volume":"37","author":"M Orth","year":"2018","unstructured":"Orth M, Unger K, Schoetz U, Belka C, Lauber K. Taxane-mediated radiosensitization derives from chromosomal missegregation on tripolar mitotic spindles orchestrated by AURKA and TPX2. Oncogene. 2018;37:52\u201362.","journal-title":"Oncogene"},{"key":"8579_CR42","doi-asserted-by":"publisher","first-page":"7305","DOI":"10.1038\/sj.onc.1209735","volume":"25","author":"L Hui","year":"2006","unstructured":"Hui L, Zheng Y, Yan Y, Bargonetti J, Foster DA. Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D. Oncogene. 2006;25:7305\u201310.","journal-title":"Oncogene"},{"key":"8579_CR43","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s41571-022-00668-4","volume":"19","author":"CA Schmitt","year":"2022","unstructured":"Schmitt CA, Wang B, Demaria M. Senescence and cancer \u2014 role and therapeutic opportunities. Nat Rev Clin Oncol. 2022;19:619\u201336.","journal-title":"Nat Rev Clin Oncol"},{"key":"8579_CR44","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/s41568-022-00450-9","volume":"22","author":"L Wang","year":"2022","unstructured":"Wang L, Lankhorst L, Bernards R. Exploiting senescence for the treatment of cancer. Nat Rev Cancer. 2022;22:340\u201355.","journal-title":"Nat Rev Cancer"},{"key":"8579_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2024.11.001","volume":"108","author":"K Shimizu","year":"2025","unstructured":"Shimizu K, Inuzuka H, Tokunaga F. The interplay between cell death and senescence in cancer. Semin Cancer Biol. 2025;108:1\u201316.","journal-title":"Semin Cancer Biol"},{"key":"8579_CR46","doi-asserted-by":"crossref","unstructured":"Jochems F, Thijssen B, De Conti G, Jansen R, Pogacar Z, Groot K, et al. The cancer SENESCopedia: a delineation of cancer cell senescence. Cell Rep. 2021;36:109441.","DOI":"10.1016\/j.celrep.2021.109441"},{"key":"8579_CR47","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.celrep.2017.09.085","volume":"21","author":"L Wang","year":"2017","unstructured":"Wang L, Leite de Oliveira R, Wang C, Fernandes Neto JM, Mainardi S, Evers B, et al. High-throughput functional genetic and compound screens identify targets for senescence induction in cancer. Cell Rep. 2017;21:773\u201383.","journal-title":"Cell Rep"},{"key":"8579_CR48","doi-asserted-by":"crossref","unstructured":"Conway PJ, De La Pe\u00f1a Avalos B, Dao J, Montagnino S, Kovalskyy D., Dray E, et al. Aurkin-A, a TPX2-aurora a small molecule inhibitor disrupts Alisertib-induced polyploidy in aggressive diffuse large B cell lymphoma. Neoplasia. 2024;55:101014.","DOI":"10.1016\/j.neo.2024.101014"},{"key":"8579_CR49","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1002\/mc.22202","volume":"54","author":"T Wu","year":"2015","unstructured":"Wu T, Harder BG, Wong PK, Lang JE, Zhang DD. Oxidative stress, mammospheres and Nrf2\u2013new implication for breast cancer therapy? Mol Carcinog. 2015;54:1494\u2013502.","journal-title":"Mol Carcinog"},{"key":"8579_CR50","doi-asserted-by":"publisher","first-page":"117","DOI":"10.5483\/BMBRep.2017.50.3.222","volume":"50","author":"K Eun","year":"2017","unstructured":"Eun K, Ham SW, Kim H. Cancer stem cell heterogeneity: origin and new perspectives on CSC targeting. BMB Rep. 2017;50:117\u201325.","journal-title":"BMB Rep"},{"key":"8579_CR51","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.3390\/cancers15051474","volume":"15","author":"V Stagni","year":"2023","unstructured":"Stagni V, Kaminari A, Contadini C, Baril\u00e0 D, Sessa RL, Sideratou Z, et al. A triphenylphosphonium-functionalized delivery system for an ATM kinase inhibitor that ameliorates doxorubicin resistance in breast carcinoma mammospheres. Cancers. 2023;15:1474.","journal-title":"Cancers"},{"key":"8579_CR52","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/jcc.20566","volume":"28","author":"IS Moreira","year":"2007","unstructured":"Moreira IS, Fernandes PA, Ramos MJ. Computational alanine scanning mutagenesis - an improved methodological approach. J Comput Chem. 2007;28:644\u201354.","journal-title":"J Comput Chem"},{"key":"8579_CR53","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J Comput Chem. 2010;31:455.","journal-title":"J Comput Chem"},{"key":"8579_CR54","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","volume":"61","author":"J Eberhardt","year":"2021","unstructured":"Eberhardt J, Santos-Martins D, Tillack AF, Forli S. AutoDock Vina 1.2.0: new docking methods expanded force field, and Python bindings. J Chem Inf Model. 2021;61:3891\u20138.","journal-title":"J Chem Inf Model"},{"key":"8579_CR55","doi-asserted-by":"publisher","first-page":"13122","DOI":"10.3390\/ijms222313122","volume":"22","author":"D Boi","year":"2021","unstructured":"Boi D, Souvalidou F, Capelli D, Polverino F, Marini G, Montanari R, et al. Pha-680626 is an effective inhibitor of the interaction between aurora-a and n-myc. Int J Mol Sci. 2021;22:13122.","journal-title":"Int J Mol Sci"},{"key":"8579_CR56","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nprot.2007.73","volume":"2","author":"H Hern\u00e1ndez","year":"2007","unstructured":"Hern\u00e1ndez H, Robinson CV. Determining the stoichiometry and interactions of macromolecular assemblies from mass spectrometry. Nat Protoc. 2007;2:715\u201326.","journal-title":"Nat Protoc"},{"key":"8579_CR57","doi-asserted-by":"publisher","first-page":"4876","DOI":"10.1093\/bioinformatics\/btab436","volume":"37","author":"D Quetschlich","year":"2021","unstructured":"Quetschlich D, Esser KT, Newport TD, Fiorentino F, Shutin D, Chen S, et al. NaViA: a program for the visual analysis of complex mass spectra. Bioinformatics. 2021;37:4876\u20138.","journal-title":"Bioinformatics"},{"key":"8579_CR58","doi-asserted-by":"publisher","first-page":"4370","DOI":"10.1021\/acs.analchem.5b00140","volume":"87","author":"MT Marty","year":"2015","unstructured":"Marty MT, Baldwin AJ, Marklund EG, Hochberg GK, Benesch JL, Robinson CV. Bayesian deconvolution of mass and ion mobility spectra: from binary interactions to polydisperse ensembles. Anal Chem. 2015;87:4370\u20136.","journal-title":"Anal Chem"},{"key":"8579_CR59","doi-asserted-by":"publisher","first-page":"10747","DOI":"10.1039\/D1CC04186J","volume":"57","author":"F Fiorentino","year":"2021","unstructured":"Fiorentino F, Rotili D, Mai A, Bolla JR, Robinson CV. Mass spectrometry enables the discovery of inhibitors of an LPS transport assembly via disruption of protein\u2013protein interactions. Chem Commun. 2021;57:10747\u201350.","journal-title":"Chem Commun"},{"key":"8579_CR60","doi-asserted-by":"crossref","unstructured":"Genovese I, Fiorillo A, Ilari A, Masciarelli S, Fazi F, Colotti G. Binding of doxorubicin to Sorcin impairs cell death and increases drug resistance in cancer cells. Cell Death Dis. 2017;8:e2950.","DOI":"10.1038\/cddis.2017.342"},{"key":"8579_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03063-y","volume":"11","author":"I Genovese","year":"2020","unstructured":"Genovese I, Giamogante F, Barazzuol L, Battista T, Fiorillo A, Vicario M, et al. Sorcin is an early marker of neurodegeneration, Ca2+ dysregulation and endoplasmic reticulum stress associated to neurodegenerative diseases. Cell Death Dis. 2020;11:861.","journal-title":"Cell Death Dis"},{"key":"8579_CR62","doi-asserted-by":"publisher","first-page":"374","DOI":"10.3390\/cells9020374","volume":"9","author":"FD Naso","year":"2020","unstructured":"Naso FD, Sterbini V, Crecca E, Asteriti IA, Russo AD, Giubettini M, et al. Excess TPX2 interferes with microtubule disassembly and nuclei reformation at mitotic exit. Cells. 2020;9:374.","journal-title":"Cells"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08579-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08579-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08579-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T20:02:40Z","timestamp":1774987360000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08579-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8579"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08579-3","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"17 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. For Patient-derived organoids, details are included in the \u201cMaterials and methods\u201d section.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"356"}}